Highlighting how technology and mindset shifts can help expand breast cancer research leadership beyond high-income countries ...

Medidata will be expanding its long-standing partnership with Sanofi, now leveraging Medidata Patient, Data, and Study Experiences within the collaboration. The ecosystem of tools aims to address ...

Today’s ACT Brief explores how eConsent is modernizing participant engagement, highlights new data on global representation in breast cancer trials, and examines Moderna’s decision to halt its Phase ...

Examining how shifting leadership patterns in breast cancer research signal growing international participation—and the ...

Revisit top insights from SCOPE Summit 2025, where industry leaders explored how artificial intelligence is reshaping trial ...

Cross-generational access: Digital technology adoption spans all age groups, with older adults becoming increasingly more comfortable using smartphones and tablets. Features like audio-visual consent, ...

At ESMO 2025, AstraZeneca reported that Imfinzi plus BCG therapy reduced the risk of recurrence or death by 32% in patients ...

In today’s ACT Brief, we revisit key insights from SCOPE Summit 2025 on AI and pragmatic trials, examine Genentech’s Phase III vamikibart data in uveitic macular edema, and highlight MJH Life Sciences ...

Unlock the advantage of pragmatic trials and improve efficiency and real-world relevance to reduce risk and strengthen ...

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...

Edwards also noted the shift towards adaptive trial designs and the benefits of staying with the same CRO for continuity.

At AAO 2025, Genentech reported that vamikibart, a first-in-class IL-6–targeted antibody, led to rapid improvements in visual acuity and macular thickness in patients with uveitic macular edema, ...